Leadership with
proven experience
Philip Just Larsen
MD, PhD
Chief Executive Officer
Philip joined Antag Therapeutics as CEO in 2026, bringing more than 20 years of experience leading research divisions in the pharmaceutical industry. He acted as chairman of Antag’s Board of Directors from January 2018 until March 2026.
Previously, Philip was the CEO of Sixpeaks Bio AG and Senior Vice President, Global Head of Pharma Research and Early Development Precision Medicine at Bayer AG. Philip has held R&D leadership roles at several global pharmaceutical companies, including Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. As CSO for Diabetes and Obesity at Eli Lilly, he led the initiation of the dual incretin agonist programmes that resulted in tirzepatide and mazdutide. He holds an MD and a PhD in neuroscience from the University of Copenhagen.
Alexander H. Sparre-Ulrich
MSc, PhD
Co-founder & Chief Operating Officer
As a translational scientist, his career spans from fundamental pharmacological research to initiating clinical development of a novel obesity treatment. He holds a PhD from the University of Copenhagen, where he has also served as both Assistant Professor and External Lecturer.
Jakob Dynnes Hansen
MSc, MBA
Chief Financial Officer
Jakob joined Antag Therapeutics as Chief Financial Officer in June 2017, bringing 25 years of management experience from biotech firms and investment banks.
Prior to his role at Antag, he held CFO positions at Asarina Pharma, Acesion Pharma, the Evolva Group and Zealand Pharma. Earlier in his career, he held senior positions in corporate finance at Unibank (now Nordea) and market research roles at Novo Nordisk. He holds an MSc from University of Copenhagen and an MBA from INSEAD.
Mads Tang-Christensen
MD, PhD
Chief Scientific Officer
Mads joined Antag Therapeutics as Chief Scientific Officer in September 2022, bringing more than 20 years of leadership experience in obesity and metabolic disease research across the pharmaceutical and biotech sectors. Prior to joining Antag, Mads held various leadership roles in diabetes and obesity at Novo Nordisk, most recently Corporate Vice President, where he was the Global Head of obesity and liver disease.
Mads co-founded Gubra Aps and Rheoscience A/S, where he held executive positions. He is currently a Professor of Physiology at Monash University, Melbourne, and holds Chief Scientific Officer roles at Incipiam Pharma and Embark Laboratories. He has authored close to 50 scientific publications and holds an MD and a PhD in Neurobiology from the University of Copenhagen.
Richard Nkulikiyinka
MSc, MB BChir, MRCP
Chief Medical Officer
He spent 15 years at Bayer, where he held several senior leadership positions, including Vice President, Head of the Therapeutic Area Cardiology, Nephrology & Pulmonology within Global Clinical Development and Operations. Richard currently serves as Chief Development Officer at GenKardia, Clinical Development Advisor at Logan Bioinformatics, and is a member of the Scientific Advisory Board at MultiOmic Health. He holds a Medical Doctorate from the University of Cambridge.
Jens Chr. Norrild
MSc, PhD
VP, Head of CMC
Jens was appointed VP & Head of CMC at Antag Therapeutics in March 2025, bringing over 15 years of experience in drug development and CMC leadership. He was most recently Chief CDMO Officer at Bioneer A/S and part of the management team. Before that, he was Vice President of CMC & Quality at Cytoki Pharma ApS, and earlier held several senior roles at Novo Nordisk, including CMC Project Director. Earlier in his career, after serving as Assistant Research Professor at the University of Copenhagen, Jens held several positions in Danish Biotech companies. He holds a PhD in Carbohydrate Chemistry from the Technical University of Denmark, a Master’s in Organic Chemistry from University of Copenhagen, and has an Executive certificate in Managing Medical Product Innovation from Copenhagen Business School.